tiprankstipranks
Advertisement
Advertisement

AGIO Stock Latest News

Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
Company AnnouncementsAgios Pharma Shareholders Expand Equity Plan, Reelect Directors
10d ago
8K
AGIO
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat
PremiumCompany Announcements
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat
10d ago
AGIO
Agios Maintained at Hold as Analyst Keeps $32 Price Target Amid Clinical Progress and Competitive Sickle Cell Risks
PremiumRatings
Agios Maintained at Hold as Analyst Keeps $32 Price Target Amid Clinical Progress and Competitive Sickle Cell Risks
13d ago
AGIO
Emily Bodnar Reiterates Buy on Agios, Citing Strong Mitapivat SCD Profile and Raising Price Target to $54
PremiumRatings
Emily Bodnar Reiterates Buy on Agios, Citing Strong Mitapivat SCD Profile and Raising Price Target to $54
13d ago
AGIO
Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright
PremiumThe Fly
Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright
13d ago
AGIO
Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat
PremiumThe FlyAgios Pharmaceuticals presented results from Phase 3 trial of mitapivat
14d ago
AGIO
Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan
Premium
The Fly
Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan
17d ago
AGIO
Agios Pharma Kept at Hold as Analyst Weighs Cevidoplenib Opportunity Against Execution Risks; $32 Price Target Reaffirmed
Premium
Ratings
Agios Pharma Kept at Hold as Analyst Weighs Cevidoplenib Opportunity Against Execution Risks; $32 Price Target Reaffirmed
26d ago
AGIO
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
PremiumThe Fly
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
27d ago
AGIO
Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path
PremiumCompany Announcements
Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path
30d ago
AGIO
Agios Advances Pediatric Mitapivat Trial in Transfusion-Dependent Thalassemia: What Investors Should Watch
PremiumCompany Announcements
Agios Advances Pediatric Mitapivat Trial in Transfusion-Dependent Thalassemia: What Investors Should Watch
30d ago
AGIO
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
30d ago
AGIO
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes
PremiumThe FlyAgios will not advance tebapivat in lower-risk myelodysplastic syndromes
30d ago
AGIO
Agios announces EC grants marketing authorization for PYRUKYND
Premium
The Fly
Agios announces EC grants marketing authorization for PYRUKYND
1M ago
AGIO
Tessa Romero Reiterates Hold on Agios Pharma as Mitapivat Momentum Balances Competitive and Regulatory Uncertainties
Premium
Ratings
Tessa Romero Reiterates Hold on Agios Pharma as Mitapivat Momentum Balances Competitive and Regulatory Uncertainties
2M ago
AGIO
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
PremiumThe Fly
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
2M ago
AGIO
Agios Pharmaceuticals to present mitapivat data at EHA Congress
PremiumThe Fly
Agios Pharmaceuticals to present mitapivat data at EHA Congress
2M ago
AGIO
Agios Pharmaceuticals Earnings Call Signals Strong Momentum
PremiumCompany Announcements
Agios Pharmaceuticals Earnings Call Signals Strong Momentum
2M ago
AGIO
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
2M ago
AGIO
Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
PremiumThe FlyAgios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
2M ago
AGIO
Is AGIO a Buy, Before Earnings?
Premium
Pre-Earnings
Is AGIO a Buy, Before Earnings?
2M ago
AGIO
Agios Pharmaceuticals price target lowered to $41 from $44 at BofA
Premium
The Fly
Agios Pharmaceuticals price target lowered to $41 from $44 at BofA
2M ago
NVO
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >